智通财经APP讯,泰德医药(03880)发布公告,本公司于2026年2月5日收到中国证监会就转换并上市向本公司发出的备案通知书。根据备案通知书,有关转换并上市的中国证监会备案已告完成,若本公司自备案通知书出具之日起12个月内未完成股份转换,拟继续推进的,应当向中国证监会更新备案材料。
于本公告日期,转换并上市的实施计划详情尚未最终确定。本公司将根据上市规则及适用法律法规的要求就转换并上市的进展情况作出进一步公布。
智通财经APP讯,泰德医药(03880)发布公告,本公司于2026年2月5日收到中国证监会就转换并上市向本公司发出的备案通知书。根据备案通知书,有关转换并上市的中国证监会备案已告完成,若本公司自备案通知书出具之日起12个月内未完成股份转换,拟继续推进的,应当向中国证监会更新备案材料。
于本公告日期,转换并上市的实施计划详情尚未最终确定。本公司将根据上市规则及适用法律法规的要求就转换并上市的进展情况作出进一步公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.